Tim Hardman Group Member

The Managing Director of Niche Science & Technology Ltd., a 30+ person bespoke services CRO based in the UK, Dr Tim Hardman founded the company in 1998. With over 40 years of experience in clinical research, Dr Hardman is highly regarded for his expertise in translational science, clinical pharmacology, and the strategic design and implementation of clinical studies. Dr Hardman began his career with a solid foundation in pharmacology, earning his doctorate in the field and gaining early experience in academic and clinical research settings. His career path saw him working in the field of regulatory science, where he developed a deep understanding of clinical trial design, data interpretation, and regulatory requirements across various therapeutic areas. Dr Hardman’s expertise spans early-phase studies, first-in-human trials, and advanced regulatory submissions, helping numerous clients bring innovative therapies from concept to clinical reality. For the last 6 years he has headed up the Association for Human Pharmacology in the Pharmaceutical Industry.

As the founder and Managing Director of Niche Science & Technology, Dr Hardman has built the company with a vision to deliver bespoke, high-quality research and regulatory support services. He leads a multidisciplinary team of scientists, clinicians, and regulatory experts dedicated to optimizing clinical programs through strategic insights and a rigorous, evidence-based approach. Under his leadership, Niche has become known for its client-centred philosophy, offering tailored solutions that address the unique scientific and regulatory challenges faced by each project.

A hands-on and highly inspirational leader, Tim radiates a determination born of many years training on the athletics track, and the same desire for success displayed in his sporting career pervades every aspect of his working life. He is passionate about advancing therapeutic innovation and improving patient outcomes through science-driven development. His commitment to integrity, scientific rigour, and collaboration has established him as a respected leader in the clinical research industry. He retains the scientific bent and inquiring mind that emerged from his academic training in pharmacology, and he continues to be a prolific writer, publishing widely cited papers on his favoured area of diabetes in prestigious journals. He was recently awarded an Honorary Fellowship from St George’s University Medical School for his contributions to medical science and his inspirational acceptance speech has become a social media phenomenon.

Niche Science & Technology Ltd